Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
Profitability Metrics
Gross Margin
57.78%
Operating Margin
22.70%
Net Margin
16.71%
Efficiency Metrics
Revenue per Expense Ratio
1.29
R&D as % of Revenue
4.48%
Earnings Quality
EBITDA Margin
24.16%
Income Tax Rate
23.45%
EPS
3.4100000000
Balance Sheet Analysis
Current Ratio
1.64
Cash Ratio
0.60
Working Capital
$808.00M
Debt to Equity
2.01
Debt to Assets
48.78%
Equity Ratio
24.29%
Cash Flow Analysis
Operating Cash Flow Ratio
19.18%
Free Cash Flow Ratio
18.10%
CapEx to Revenue
1.08%
Dividends Paid
No dividends paid
Stock Buybacks
$147.00M
Total Shareholder Returns
$147.00M
Cash Position Change
76,200,000,000.0%
Key Takeaways (2023 FY)
Increased R&D investment by 3.69%
Detailed Growth Metrics
Core Performance
Revenue
2.91%
Net Income
-0.71%
EPS
-0.58%
Operating Income
5.75%
Operational Efficiency
R&D Expenses
3.69%
SG&A Expenses
4.21%
Operating Cash Flow
10.69%
Free Cash Flow
8.73%
Balance Sheet Health
Assets
17.99%
Debt
2,157.72%
Book Value per Share
-57.18%
Inventory
-13.91%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
0.12%
Long Term Trends
3Y Revenue/Share
15.34%
5Y Revenue/Share
15.34%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%